CliffBio
small molecule

LOREEV XR

LORAZEPAM

Loss of exclusivityJanuary 2034latest FDA-listed patent expiry
CompanyAlmatica Pharma →View the full company profile on CliffBio

Drug detail

Brand nameLOREEV XR
Active ingredientLORAZEPAM
Strength1.5MG
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2022
Marketing statusRX

Listed patents

PatentExpiresType
8999393January 2034product

More from Almatica Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

LOREEV XR patent cliff — loss of exclusivity January 2034 | CliffBio